What causes resistance to Gleevec?
Acquired point mutations within the target genes (Bcr-Abl, KIT and PDGFRα) are a major mechanism of resistance to Gleevec in some patients with hematologic malignance. The mutations are believed to block the binding of Gleevec to ATP binding pockets of these tyrosine kinases.
What is Gleevec resistance?
The most common mechanism of resistance to Gleevec is due to mutations in the ABL kinase domain that affect the ability of Gleevec to bind to the active site. This may occur through steric interference within the site itself or by changing the conformation of the fusion protein so that the binding site is masked.
What is imatinib resistance mutation analysis?
This test is useful for detecting over 90 known and novel mutations in ABL kinase domain of Ph chromosome including T3151 and P-loop mutations responsible for resistance to Imatinib in CML patients.
Why does imatinib stop working?
In some patients, imatinib seems to stop working over time. This is known as imatinib resistance. Resistance to imatinib seems to be caused by changes in the genes of the CML cells.
What to do when Gleevec stops working?
Go to an increased dose of imatinib if tolerated or consider switching to a different kinase inhibitor such as sunitinib (as 2nd line) and then regorafenib (as 3rd line).
How common is imatinib resistance?
Primary imatinib resistance was found in 50% of PDGFRA-mutant tumors, 33.4% of wild-type tumors, and 8.9% of c-Kit-mutated tumors. C-Kit exon 9-mutant tumors showed primary resistance more frequently than exon 11-mutant and other tumors.
How can the drug Gleevec become ineffective for some CML patients?
Researchers have identified specific mutations in a rogue gene that render the drug Gleevec ineffective in some patients who have chronic myeloid leukemia. The studies could provide new information that may improve the effectiveness of second-generation drugs for chronic myeloid leukemia (CML).
Which is a comprehensive test for mutation analysis of resistant imatinib patients in CML?
Focus Test Summary Detects over all 90 known as well as novel mutation in the ABL kinase domain (at codon 219-506) of Ph chromosome including T3151 & P- loop mutations responsible for resistance to Imatinib.
How long is imatinib effective?
Optimal duration of therapy is unknown but generally imatinib should be continued for 6–9 months, after which additional tumor shrinkage is usually minor.
What is BCR-ABL test?
A BCR-ABL genetic test looks for a genetic mutation (change) on a specific chromosome. Chromosomes are the parts of your cells that contain your genes. Genes are parts of DNA passed down from your mother and father. They carry information that determines your unique traits, such as height and eye color.
How long does CML stay in remission?
About two-thirds of patients in the study remained in remission from CML 3 years after stopping treatment and most of them were still in remission at the 4-year mark. Many reported improvements in common treatment-related symptoms, particularly fatigue and diarrhea.
What is BCR-ABL mutation analysis?
This test is used to determine if a mutation is present that would interfere with response to TKI therapy in Philadelphia chromosome positive (Ph+) lymphoblastic leukemia or chronic myelogenous leukemia (CML). The test detects all common mutations, including T315I.
Can you take a break from Gleevec?
New treatment guidelines in the U.S. say certain patients can consider stopping Gleevec or similar drugs which were long thought to be needed for the rest of their lives. It’s just a pill or two a day but the drugs are expensive and have side effects.
When should I stop Gleevec?
Stopping Gleevec and other drugs before surgery According to the NCCN guidelines (Version 2.2018), imatinib can be stopped right before surgery and restarted as soon as the patient is able to tolerate oral medications.
What are the long term effects of taking Gleevec?
Some of the side effects seen in clinical studies can happen with long-term use of Gleevec. These include heart problems, such as congestive heart failure and left-sided heart failure. In a clinical study, more than 500 people who took Gleevec for chronic myeloid leukemia (CML) were followed for up to 11 years.
How does CML mutate?
Most cases of CML start during cell division, when DNA is “swapped” between chromosomes 9 and 22. Part of chromosome 9 goes to 22 and part of 22 goes to 9. The swapping of DNA between the chromosomes leads to the formation of a new gene (an oncogene) called BCR-ABL.